Middle East And Africa Diabetes Devices Market

Market Overview

The global Middle East And Africa Diabetes Devices Market was valued at approximately USD 2.53 billion in 2025 and is projected to reach USD 59.69 billion by 2033, growing at a CAGR of 6.62% during the forecast period (2025–2033).

Diabetes devices are valuable tools to track and manage blood glucoses levels or administer insulin in relation to diabetic needs. The types of diabetes devices are blood glucose monitoring systems: blood t glucose monitoring systems (glucometers and continuous glucose monitoring (CGM)) and insulin delivery systems (pens, pumps, syringes). Diabetes devices are important for patients to manage glycemic control and minimize complication and improve patient’s quality of life.

In the Middle East and Africa, the diabetes devices market is driven by trends such as urbanization, sedentary lifestyles and poor eating choices leading to increased rates of diabetes, etc. Together, these elements result in increased rates of diabetes and a growing diabetes devices market. Additionally, government promotion of chronic disease awareness and initiated efforts to control chronic diseases, expanding healthcare infrastructure are promoting the acceptance of advanced diabetes devices in the Middle East and Africa.

Market Dynamics

Market Drivers 

Rising Prevalence of Diabetes and Lifestyle-Related Risk Factors

The Middle East and Africa diabetes devices market is growing with the increasing incidence of diabetes in the region. As per the International Diabetes Federation (IDF), the Middle East and North Africa (MENA) region housed more than 73 million adults with diabetes, which is forecasted to reach 136 million by 2045. Obesity, urban and sedentary lifestyles, and unhealthy dietary patterns are the causes of diabetes in the MENA region.

Gulf nations like Saudi Arabia, Kuwait, and the UAE have some of the highest rates of diabetes in the world, with more than 15–20% of their adult populations having the disease. For instance, according to the latest Saudi Ministry of Health study in 2023, approximately 1 out of 5 adults in Saudi Arabia has diabetes, thus placing further demand on blood glucose monitoring and insulin equipment.

In addition, with greater awareness of diabetic complication risks, patients are increasingly taking an active role in monitoring their blood glucose regularly and administering insulin therapeutically, leading to growing use of self-monitoring blood glucose (SMBG) meters and continuous glucose monitoring (CGM) devices. Government-led national screening and awareness campaigns, like the UAE “Diabetes Screening and Awareness Campaign” in 2023, will additionally drive the demand for diabetes devices in the MENA region.

Technological Advancements and Expanding Access to Healthcare Infrastructure

The pace of technological innovation in diabetes care is disrupting the landscape in the Middle East and Africa, and driving demand for sophisticated diabetes devices. Fast becoming indispensable are devices such as flash glucose monitors (i.e., Abbott’s FreeStyle Libre), glucometers that can communicate to smartphones, and smart insulin pens; these devices are being adopted quickly for their ease of use, accuracy, and interoperability with digital health communication platforms.

For example, in 2023, Medtronic engaged with the Saudi Ministry of Health to expand access to insulin pump therapy and its digital diabetes management services across the major government hospitals operating in the Arabian Kingdom. Furthermore, several governments in the Middle East and Africa are making significant investments in healthcare infrastructure and adopting digital health. For example, the Saudi Vision 2030 initiative in 2022 allocated significant funds towards non-communicable disease management, including the more complex comprehensive care that diabetes represents.

The United Arab Emirates is developing their digital healthcare platforms and e-pharmacy channels to expand access to glucometers and insulin device options. And, there are more public-private partnerships emerging, for instance, the Novo Nordisk and Egypt Ministry of Health partnership in 2023 is expected to improve diabetes care provision through the availability of devices and training healthcare providers. The shift in technological capabilities, as well as improved access to diagnostics and affordability through local manufacturing and distribution within these markets, continues to strengthen their overall potential market size for diabetes devices in the future.

Market Restraints

High Cost of Advanced Diabetes Devices and Limited Reimbursement Policies

A significant limiter to the growth of the Middle East and Africa diabetes devices market is the high cost of advanced technologies, specifically that many of the available advanced diabetes devices may not have insurance reimbursement plans available. Technological advancements in CGMs and insulin dosing devices have presented some of the best solutions to managing diabetes to date, but for many patients, especially in low- to middle-income countries, they are simply out of reach.                            

For example, the FreeStyle Libre system or the Dexcom G6 can cost more than a $1,000 per year, not including the cost of the sensors and ongoing maintenance for the use of the device, which just cannot be afforded by many patients who do not have health insurance. For example, insulin pump manufacturers like Medtronic or Tandem Diabetes Care sell some of their insulin dosing devices for an estimated $4,000 to $6,000 per device without insurance coverage, which means that a projected majority of patients, especially in low-income, rural communities, will never be able to afford an insulin device, let alone an insulin pump.

Segmental Analysis

By Product Type

The MEA diabetes devices market is supported by the increasing prevalence of diabetes, urbanization, and awareness of the importance of healthcare. Blood Glucose Monitoring Devices will dominate the market with the qualitative and quantitative use of testing sugar levels in patients (i.e. their widespread use in tracking the blood sugar level of patients). Self-Monitoring Devices and Glucose Meters are both demonstrating rapid growth due to the shift towards the home care environment.

Test Strips will present recurring demand and represent a sizeable segment of revenue. Lancets are important and commonly used devices in diabetes management, especially but unit development and growth in painless lancets. Hemoglobin A1C Testing Kits are growing in popularity due to the growing need for long-term weekly or monthly glucose control assessment or monitoring for patients. The market overall is growing with increasing access to them, affordability, and support of government.

By End-Users

In 2024, hospitals retained the largest market share, largely due to the sheer volume of inpatient and urgent care diabetes services. Tertiary hospitals in Saudi Arabia, the UAE, and South Africa utilize advanced diagnostics, including insulin pumps, making them the predominant technology shift in the region.

Home Care is becoming a high-growth area due to the emergence of the remote monitoring economy, increasing patient self-care preferences, and an aging majority with multiple chronic conditions. All remote monitoring devices use glucose meters or continuous glucose monitors (CGMs), which patients have adapted to technology for managing long-term Type 2 diabetes. Diagnostic centers provide routine diabetes screening and early detection of diabetes risks, especially in more urban areas characterized by high patient volumes.

These centers are now using and expanding their use of HbA1c testing kits and digital glucose monitors to provide an efficient, reliable diagnostic service. Clinics in semi-urban and rural areas will slowly expand in the market as basic diagnostic capability and insulin delivery access are developed across the region, in a public-private healthcare drive, a patient in the area can access basic diabetes services like the rest of the population.

By Distribution Channel

Hospital Pharmacies are the highest in revenue as a market due to supply contracts. Moreover, their services are offered immediately following clinical consultation or discharge once patient care is complete. Retail Pharmacies are the “most accessible realization” of the out-of-hospital sales channel. They lead in out-of-hospital sales volume – especially in glucose strips, glucose meters, and insulin pens.

Their available footprint includes urban and suburban locations and impacts sales penetration into both settings.  Online pharmacies are growing fastest from health spending through e-commerce activity, digital health promoters and government intentions to improve medicine accessibility. Notably, in response to COVID-19, online sales of diabetes devices surged in the UAE and Saudi Arabia, as consumer demand improved for digital consultations as well as home deliveries.

Regional Analysis

North America

North America maintains the largest market share in the global diabetes devices market at 38.4% (2024). Per capita prevalence of diabetes is high in North America, with the region also having the most robust reimbursement pathways and quicker deployment of technological advancements in digital health.

The United States leads the way in decreasing morbidity related to diabetes, stemming from an entrenched use of continuous glucose monitors (CGMs), insulin pumps, and connected mobile applications to more effectively manage diabetes. Impulses to support the uptake of diabetes devices include continued research and development (R&D), funding from the government for health initiatives, and health insurance pathways for advanced devices.

Europe

Europe continues to play a critical role in the global diabetes devices market, with a significant presence in major economies such as Germany, the UK, France, and the Netherlands, all of which benefit from established diabetes management systems and strong health care. Europe also benefits from an aging population, high levels of awareness, in addition to recent public health initiatives. For instance, two recent initiatives that are more universal at the EU and country level include the European Diabetes Forum (EUDF) as well as national reimbursement roads, which support insulin delivery systems and self-monitoring blood glucose devices.

Asia-Pacific

Asia-Pacific is projected to be the region with the highest growth rates, projected to grow at a CAGR of 8.1% during the forecast period. This growth is driven by rapid urbanisation, increasing healthcare expenditure and the rapid rise in the prevalence of Type 2 diabetes in countries like China, India and Japan. China alone has more than 140 million diabetes patients, which represents a significant opportunity for glucose monitors and insulin pens. Increased adoption of digital health technologies along with local production, is also contributing to the affordability and accessibility of diabetes products throughout the region.

Latin America

Latin America is projected to grow at a moderate pace, with an increase in awareness and better access to diabetes diagnosis and treatment in Brazil, Mexico and Argentina driving growth. Nevertheless, there are still challenges, including economic inequalities and a lack of access to advanced diabetes technologies in rural areas. Government health campaigns and partnerships with global diabetes societies are leading to increased penetration of insulin pens, glucometers and test strips.

Middle East and Africa

The Middle East and Africa are regions with considerable growth opportunities. Countries with particularly high diabetes rates, like Saudi Arabia, the UAE, Egypt, and South Africa, have notable growth potential. In 2024, this region will represent 7.6% of the global diabetes devices market, and healthcare investment strategies include the building of healthcare infrastructure, national diabetes programs, and public-private partnerships.

However, while there appears to be an excellent growth opportunity, many barriers – including high device costs, limited reimbursement, and a lack of access to devices in under-serviced rural areas – are holding back the full potential of this region.

Recent Development

1. April 2025: Submitted FDA application for an interoperable CGM in partnership with Abbott, aiming to integrate Abbott’s sensor with Medtronic smart dosing devices.
2. April 2025: (ATTD conference): Presented data on upcoming Dexcom G7 15‑Day system with a 8.0% MARD accuracy and integration into automated insulin delivery (AID) and smart pen systems March
3. 2024: FDA cleared Stelo by Dexcom, the first OTC glucose biosensor in the U.S., for adults with Type 2 diabetes not using insulin.